search
for
 About Bioline  All Journals  Testimonials  Membership  News


VITAE Academia Biomédica Digital
Centro de Análisis de Imágenes Biomédicas Computarizadas-CAIBC0
ISSN: 1317-987x
No. 44, 2010
Bioline Code: va10027
Full paper language: Spanish
Document type: Research Article
Document available free of charge

VITAE Academia Biomédica Digital, No. 44, 2010

 en Prevalence and susceptibility of Candida check for this species in other resources spp to fluconazol at an Anticancer Society clinic in Maracay, Venezuela.
Llovera Suarez, Vilma J.

Abstract

In order to establish the prevalence of VVC, to register the clinical manifestations and associated risk factors as well as, to identify Candida species and determining fluconazole susceptibility by two methods, 294 women were studied who attended the Anticancer Society clinic from June to November 2006. The VVC prevalence was 19.39%. The following species were identified: C. albicans 42.11% (24/57), followed by C. glabrata 33.33% (19/57), C. guilliermondii 5.26% (03/57), C. parapsilosis 3.51% (02/57), Candida spp 5.26% (03/57), C. tropicalis 1.75% (01/57) and C. kefyr 1.75% (01/57). It was found that itching, burning and vaginal discharge represented the signs and symptoms associated to VVC (p<0.01). Ages between 20-29 years and prolonged antibiotic therapy were risk factors CVV (p<0.01). 76.19% (16) C. albicans isolates were susceptible to fluconazole for both methods with 95,24% concordance. In contrast, 100% C. glabrata isolates were resistant for the reference method showed 57.14% concordance.

Keywords
Vulvovaginal Candidosis (VVC), prevalence, fluconazole, M27-A2, M44-A

 
 es Prevalencia y sensibilidad de Candida check for this species in other resources spp a fluconazol en la clínica de la Sociedad Anticancerosa de Maracay, Venezuela.
Llovera Suarez, Vilma J.

Resumen

Para establecer la prevalencia de Candidiasis Vulvovaginal (CVV), registrar las manifestaciones clínicas y los factores de riesgo asociados así como, identificar las especies del género Candida y determinar la sensibilidad a fluconazol por dos métodos, fueron estudiadas 294 mujeres que acudieron a la Clínica de la Sociedad Anticancerosa de Junio a Noviembre de 2006. La prevalencia de CVV fue de 19,39%. Se identificó: C. albicans en 42,11% (24/57), seguida de C. glabrata 33,33% (19/57), C. guilliermondii 5,26% (03/57), C. parapsilosis 3,51% (02/57), Candida spp. 5,26% (03/57), C. tropicalis 1,75% (01/57) y C. kefyr 1,75% (01/57). El análisis estadístico reveló que el ardor, prurito y flujo fueron los signos y síntomas asociados a CVV (p<0,01). La edad entre 20-29 años y el uso prolongado de antibiótico fueron los factores de riesgo significativos (p<0,01). De las cepas de C. albicans identificadas, 16 (76,19%) fueron sensibles a fluconazol por ambos métodos con 95,24% de concordancia, las cepas de C. glabrata fueron 100% resistentes por el método de referencia exhibiendo 57,14% de concordancia.

Palabras-clave
Candidosis Vulvovaginal (CVV), Candida, fluconazol, sensibilidad, M27-A2, M44-A

 
© Copyright 2010 Academia Biomedica Digital.
Alternative site location: http://vitae.ucv.ve

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil